ArticleOdontology2026
EIF2AK2 activates autophagy via JAK2/STAT3 pathway to promote oral squamous cell carcinoma malignancy.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progression of oral squamous cell carcinoma (OSCC), a frequent cancer of the mouth, has been associated with EIF2AK2 dysregulation, but its precise mechanisms are yet to be clarified. In this study, we investigated the expression of EIF2AK2 in OSCC tissues and cell lines using publicly available databases and Western blotting. EIF2AK2 was silenced using small interfering RNA (siRNA), and its functional impact on OSCC malignant characteristics was determined using several in vitro experiments. Additionally, we determined EIF2AK2's impact on autophagy levels and the activity of mechanistic pathways. Our results demonstrate that EIF2AK2 is markedly overexpressed in OSCC tissues and cell lines, and its knockdown significantly affects OSCC malignant characteristics, such as proliferation, migration, and invasion. Furthermore, EIF2AK2 knockdown increased E-cadherin levels while reducing those of N-cadherin and Vimentin, supporting EMT suppression. It also led to reduced autophagy based on decreased LC3-II and Beclin-1 and increased p62 expressions. Moreover, inhibition of EIF2AK2 led to the downregulation of the JAK2/STAT3 axis. Collectively, these findings support EIF2AK2 as an oncogene in OSCC progression by activating autophagy through the JAK2/STAT3 pathway.
Indexed as
Identifiers
41499079What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.